VRAX and NASDAQ-VRA Related Headlines

Go Back

Dec 4, 2025 04:05PM Virax Biolabs closes $5 million private placement

Dec 4, 2025 04:05PM Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 3, 2025 01:54PM Virax Biolabs raises $5 million in private placement

Dec 3, 2025 01:53PM Virax Biolabs Group Limited Announces $5 Million Private Placement

Dec 3, 2025 07:34AM Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Nov 3, 2025 08:29AM Virax Biolabs completes UK clinical study recruitment ahead of schedule

Nov 3, 2025 08:29AM Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Jul 18, 2025 04:15PM Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

VRAX and NASDAQ-VRA Related Press Releases

Go Back

Dec 4, 2025 04:05PM Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 3, 2025 01:53PM Virax Biolabs Group Limited Announces $5 Million Private Placement

Dec 3, 2025 07:34AM Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Nov 3, 2025 08:29AM Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Jul 18, 2025 04:15PM Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

VRAX and NASDAQ-VRA Related SEC Filings

Go Back